Opiant Pharmaceuticals, Inc.Find Ratings Reports
OPIANT PHARMACEUTICALS INC's gross profit margin for the fourth quarter of its fiscal year 2020 has significantly decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. OPIANT PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 8.90 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has remained virtually unchanged only increasing by 3.12% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY20||Q4 FY19|
|Net Sales ($mil)||9.92||7.67|
|Net Income ($mil)||-0.69||1.07|
|Balance Sheet||Q4 FY20||Q4 FY19|
|Cash & Equiv. ($mil)||48.25||30.98|
|Total Assets ($mil)||60.61||40.28|
|Total Debt ($mil)||18.98||0.77|
|Profitability||Q4 FY20||Q4 FY19|
|Gross Profit Margin||-9.9||12.28|
|Return on Assets||-3.07||28.78|
|Return on Equity||-5.24||33.68|
|Debt||Q4 FY20||Q4 FY19|
|Share Data||Q4 FY20||Q4 FY19|
|Shares outstanding (mil)||4.26||4.19|
|Div / share||0.0||0.0|
|Book value / share||8.34||8.22|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||29138.0||73027.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 1.40 indicates a significant discount versus the S&P 500 average of 4.42 and a significant discount versus the subsector average of 8.25. The price-to-sales ratio is well below both the S&P 500 average and the subsector average, indicating a discount. After reviewing these and other key valuation criteria, OPIANT PHARMACEUTICALS INC proves to trade at a discount to investment alternatives.
|OPNT NM||Peers 28.89||OPNT NM||Peers 18.08|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
OPNT's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
OPNT's P/CF is negative making the measure meaningless.
|OPNT NM||Peers 15.17||OPNT NA||Peers 0.46|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
OPNT's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|OPNT 1.40||Peers 8.25||OPNT -123.11||Peers -4.29|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
OPNT is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, OPNT is expected to significantly trail its peers on the basis of its earnings growth rate.
|OPNT 1.67||Peers 10.71||OPNT -26.89||Peers 52.02|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
OPNT is trading at a significant discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
OPNT significantly trails its peers on the basis of sales growth.